167 related articles for article (PubMed ID: 38602533)
1. [Update of the German S3 guideline on renal cell carcinoma].
Doehn C; Bergmann L; Decker J; Gauler T; Grünwald V; Weikert S; Krege S
Urologie; 2024 May; 63(5):439-447. PubMed ID: 38602533
[TBL] [Abstract][Full Text] [Related]
2. The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitor-based Combination Therapies for Treatment-naive Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care.
Bedke J; Albiges L; Capitanio U; Giles RH; Hora M; Lam TB; Ljungberg B; Marconi L; Klatte T; Volpe A; Abu-Ghanem Y; Dabestani S; Pello SF; Hofmann F; Kuusk T; Tahbaz R; Powles T; Bex A
Eur Urol; 2021 Oct; 80(4):393-397. PubMed ID: 34074559
[TBL] [Abstract][Full Text] [Related]
3. Cabozantinib and nivolumab as first-line treatment in advanced renal cell carcinoma.
Vitale MG; Nasso C; Oltrecolli M; Baldessari C; Fanelli M; Dominici M; Sabbatini R
Expert Rev Anticancer Ther; 2021 Nov; 21(11):1183-1192. PubMed ID: 34424125
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and toxicity of immune checkpoint inhibitors combination therapy for advanced renal cell carcinoma: a systematic review and network meta-analysis.
Chen X; Xu Z; Wu C; Xie L; Wang P; Liu X
Front Immunol; 2024; 15():1255577. PubMed ID: 38390328
[TBL] [Abstract][Full Text] [Related]
5. Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma.
Bedke J; Albiges L; Capitanio U; Giles RH; Hora M; Lam TB; Ljungberg B; Marconi L; Klatte T; Volpe A; Abu-Ghanem Y; Dabestani S; Fernández-Pello S; Hofmann F; Kuusk T; Tahbaz R; Powles T; Bex A
Eur Urol; 2021 Mar; 79(3):339-342. PubMed ID: 33357997
[TBL] [Abstract][Full Text] [Related]
6. Immune checkpoint inhibitors combined with tyrosine kinase inhibitors or immunotherapy for treatment-naïve metastatic clear-cell renal cell carcinoma-A network meta-analysis. Focus on cabozantinib combined with nivolumab.
Niewada M; Macioch T; Konarska M; Mela A; Goszczyński A; Przekopińska B; Rajkiewicz K; Wysocki P; Krzakowski M
Front Pharmacol; 2022; 13():1063178. PubMed ID: 36937206
[No Abstract] [Full Text] [Related]
7. [Immunotherapy for renal cell carcinoma - current status].
Grimm MO; Foller S
Aktuelle Urol; 2018 Apr; 49(2):187-191. PubMed ID: 29587324
[TBL] [Abstract][Full Text] [Related]
8. First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.
Quhal F; Mori K; Bruchbacher A; Resch I; Mostafaei H; Pradere B; Schuettfort VM; Laukhtina E; Egawa S; Fajkovic H; Remzi M; Shariat SF; Schmidinger M
Eur Urol Oncol; 2021 Oct; 4(5):755-765. PubMed ID: 33757737
[TBL] [Abstract][Full Text] [Related]
9. SEOM SOGUG clinical guideline for treatment of kidney cancer (2022).
Méndez-Vidal MJ; Lázaro Quintela M; Lainez-Milagro N; Perez-Valderrama B; Suárez Rodriguez C; Arranz Arija JÁ; Peláez Fernández I; Gallardo Díaz E; Lambea Sorrosal J; González-Del-Alba A
Clin Transl Oncol; 2023 Sep; 25(9):2732-2748. PubMed ID: 37556095
[TBL] [Abstract][Full Text] [Related]
10. [German S3 guideline for renal cell carcinoma : Presentation and discussion of essential aspects for the radiation oncologist].
Müller AC; van Oorschot B; Micke O; Guckenberger M
Strahlenther Onkol; 2018 Jan; 194(1):1-8. PubMed ID: 28819766
[TBL] [Abstract][Full Text] [Related]
11. Survival by Depth of Response and Efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with Lenvatinib Plus Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Analysis of the Phase 3 Randomized CLEAR Study.
Grünwald V; Powles T; Kopyltsov E; Kozlov V; Alonso-Gordoa T; Eto M; Hutson T; Motzer R; Winquist E; Maroto P; Keam B; Procopio G; Wong S; Melichar B; Rolland F; Oya M; Rodriguez-Lopez K; Saito K; McKenzie J; Porta C
Eur Urol Oncol; 2023 Aug; 6(4):437-446. PubMed ID: 36720658
[TBL] [Abstract][Full Text] [Related]
12. [WHO classification 2016 and first S3 guidelines on renal cell cancer: What is important for the practice?].
Moch H
Pathologe; 2016 Mar; 37(2):127-33. PubMed ID: 26942728
[TBL] [Abstract][Full Text] [Related]
13. Endometrial Cancer. Guideline of the DGGG, DKG and DKH (S3-Level, AWMF Registry Number 032/034-OL, September 2022). Part 1 with Recommendations on the Epidemiology, Screening, Diagnosis and Hereditary Factors of Endometrial Cancer, Geriatric Assessment and Supply Structures.
Emons G; Steiner E; Vordermark D; Uleer C; Paradies K; Tempfer C; Aretz S; Cremer W; Hanf V; Mallmann P; Ortmann O; Römer T; Schmutzler RK; Horn LC; Kommoss S; Lax S; Schmoeckel E; Mokry T; Grab D; Reinhardt M; Steinke-Lange V; Brucker SY; Kiesel L; Witteler R; Fleisch MC; ; Friedrich M; Höcht S; Lichtenegger W; Mueller M; Runnebaum I; Feyer P; Hagen V; Juhasz-Böss I; Letsch A; Niehoff P; Zeimet AG; Battista MJ; Petru E; Widhalm S; van Oorschot B; Panke JE; Weis J; Dauelsberg T; Haase H; Beckmann MW; Jud S; Wight E; Prott FJ; Micke O; Bader W; Reents N; Henscher U; ; Schallenberg M; Rahner N; Mayr D; Kreißl M; Lindel K; Mustea A; Strnad V; Goerling U; Bauerschmitz GJ; Langrehr J; Neulen J; Ulrich UA; Nothacker MJ; Blödt S; Follmann M; Langer T; Wenzel G; Weber S; Erdogan S
Geburtshilfe Frauenheilkd; 2023 Aug; 83(8):919-962. PubMed ID: 37588260
[No Abstract] [Full Text] [Related]
14. CaboCombo: a prospective, phase IV study of first-line cabozantinib + nivolumab for advanced renal cell carcinoma.
Barthélémy P; Dutailly P; Qvick B; Perrot V; Verzoni E
Future Oncol; 2024 Apr; 20(13):811-819. PubMed ID: 37403652
[TBL] [Abstract][Full Text] [Related]
15. Evidence-based clinical practice guideline for renal cell carcinoma: the Japanese Urological Association 2011 update.
Fujioka T; Obara W;
Int J Urol; 2012 Jun; 19(6):496-503. PubMed ID: 22621218
[TBL] [Abstract][Full Text] [Related]
16. The value measurement of emerging therapeutics in renal cell carcinoma: ASCO value framework and ESMO-MCBS.
Ha H; Kang JH; Kim DY; Bae SJ; Lee HY
BMC Health Serv Res; 2022 Jul; 22(1):900. PubMed ID: 35821026
[TBL] [Abstract][Full Text] [Related]
17. Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study.
Choueiri TK; Eto M; Motzer R; De Giorgi U; Buchler T; Basappa NS; Méndez-Vidal MJ; Tjulandin S; Hoon Park S; Melichar B; Hutson T; Alemany C; McGregor B; Powles T; Grünwald V; Alekseev B; Rha SY; Kopyltsov E; Kapoor A; Alonso Gordoa T; Goh JC; Staehler M; Merchan JR; Xie R; Perini RF; Mody K; McKenzie J; Porta CG
Lancet Oncol; 2023 Mar; 24(3):228-238. PubMed ID: 36858721
[TBL] [Abstract][Full Text] [Related]
18. Systemic therapy in metastatic renal cell carcinoma (mRCC): an evidence-based recommendation of the German interdisciplinary RCC guidelines group.
Grünwald V; Bergmann L; Brehmer B; Eberhardt B; Kastrati K; Gauler T; Gehbauer G; Gschwend J; Johannsen M; Klotz T; Protzel C; Schenck M; Staehler M
World J Urol; 2022 Oct; 40(10):2381-2386. PubMed ID: 35562599
[TBL] [Abstract][Full Text] [Related]
19. A Matching-adjusted Indirect Comparison of Nivolumab Plus Cabozantinib Versus Pembrolizumab Plus Axitinib in Patients with Advanced Renal Cell Carcinoma.
McGregor B; Geynisman DM; Burotto M; Suárez C; Bourlon MT; Barata PC; Gulati S; Huo S; Ejzykowicz F; Blum SI; Del Tejo V; Hamilton M; May JR; Du EX; Wu A; Kral P; Ivanescu C; Chin A; Betts KA; Lee CH; Choueiri TK; Cella D; Porta C
Eur Urol Oncol; 2023 Jun; 6(3):339-348. PubMed ID: 36842942
[TBL] [Abstract][Full Text] [Related]
20. Supportive therapy and complementary medicine in renal cell carcinoma.
Johannsen M; Stoll C; Raida M; van Oorschot B; Flörcken A
World J Urol; 2022 Oct; 40(10):2359-2371. PubMed ID: 34821959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
